Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3457-3468

  Park, Hong Seok ^a,b   Hong, Sung Kyu ^c   Oh, Mi Mi ^a,b   Yoon, Cheol Yong ^a,b   Jeong, Seong Jin ^c   Byun, Seok Soo ^c   Cheon, Jun ^d   Lee, Sang Eun ^c   Moon, Du Geon ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

Carcinoma; Docetaxel; NVPBEZ235; Prostate; Resistance; Sunitinib

Indexed keywords

DACTOLISIB; DOCETAXEL; EVEROLIMUS; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CASPASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; TAXOID; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; LNCAP CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOMA; DRUG EFFECT; DRUG RESISTANCE; MALE; METABOLISM; NVP-BEZ235; PATHOLOGY; PHOSPHORYLATION; PROSTATE; RESISTANCE; TUMOR CELL LINE;

CARCINOMA; DOCETAXEL; NVP-BEZ235; PROSTATE; RESISTANCE; SUNITINIB;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INDOLES; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; QUINOLINES; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84906321821     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA and Investigators TAX: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
2. Engels FK, Sparreboom A, Mathot RA and Verweij J: Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 93: 173-177, 2005.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
4. Michels J, Montemurro T, Murray N, Kollmannsberger C and Nguyen Chi K: First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 106: 1041-1046, 2006.
5. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, Berta J, Kubista B, Dome B, Grusch M, Setinek U, Micksche M, Klepetko W and Berger W: Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 6: 852-863, 2011.
6. O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R and Lane HA: Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22: 58-78, 2011.
7. Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA and Santos L: Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res 28: 3, 2009.
8. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R and Sweeney C: The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93: 143-150, 2004.
9. Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E and Oya M: Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration-resistant prostate cancer. J Urol 191: 227-234, 2014.
10. Chou TCand Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
11. Buckwold VE, Wei J, Wenzel-Mathers M and Russell J: Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother 47: 2293-2298, 2003.
12. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD and Smee DF: Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res 94: 103-110, 2012.
13. Vilhelmova N, Jacquet R, Quideau S, Stoyanova A and Galabov AS: Three-dimensional analysis of combination effect of ellagitannins and acyclovir on herpes simplex virus types 1 and 2. Antiviral Res 89: 174-181, 2011.
14. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/AKT pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005.
15. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004.
16. Fahy BN, Schlieman MG, Virudachalam S and Bold RJ: Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198: 591-599, 2004.
17. Zhang HY, Zhang PN and Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 146: 81-86, 2009.
18. Sun CH, Chang YH and Pan CC: Activation of the PI3K/AKT/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063, 2011.
19. Huang Y, Chen Y, Mei Q, Chen Y, Yu S and Xia S: Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds. Oncol Rep 29: 2486-2492, 2013.
20. Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH and Wu YL: Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PLoS One 8: e69104, 2013.
21. Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T and Ohyashiki K: Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 15: 207-215, 2014.
22. Sharma S, Yao HP, Zhou YQ, Zhou J, Zhang R and Wang MH: Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. Mol Oncol 8: 469-482, 2014.
23. Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M and Puri N: Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-MET inhibitor resistance in non-small cell lung cancer. PLoS One 8: e78398, 2013.
24. Ding J, Romani J, Zaborski M, Macleod RA, Nagel S, Drexler HG and Quentmeier H: Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1-positive leukemia cells through translational down-regulation of MDM2. PLoS One 8: e83510, 2013.
25. Robert F, Sandler A, Schiller JH, Liu G, Harper K, Verkh L, Huang X, Ilagan J, Tye L, Chao R and Traynor AM: Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 66: 669-680, 2010.
26. Gasent JM, Grande E, Casinello J, Provencia M, Laforga JB and Alberola V: Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel. Actas Urol Esp 35: 57-60, 2011 (in Spanish).
27. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M and Iacobelli S: Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 270: 229-233, 2008.
28. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM and Milano G: Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134: 51-57, 2008.
29. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L and Hutson TE: Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 21: 319-324, 2010.
30. Michaelson MD, Oudard S, Ou YC, Sengelov L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullen A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J and Chen I: Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castrationresistant prostate cancer. J Clin Oncol 32: 76-82, 2014.
31. Ravikumar Gand Crasta JA: Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation. South Asian J Cancer 2: 87-90, 2013.
32. Wang Y, Han G, Wang K, Liu G, Wang R, Xiao H, Li X, Hou C, Shen B, Guo R, Li Y and Chen G: Tumor-Derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF. Cancer Res 74: 716-726, 2014.
33. Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu J, Xue J, Liu T, Liang Y and Wu G: MiR-200c increases the radiosensitivity of non-small cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS One 8: e78344, 2013.
34. Weyand Band von Schroeder HP: Altered VEGF-A and receptor mRNA expression profiles, and identification of VEGF144 in foetal rat calvaria cells, in coculture with microvascular endothelial cells. Cell Biol Int 37: 713-724, 2013.
35. Adamcic U, Skowronski K, Peters C, Morrison J and Coomber BL: The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia 14: 612-623, 2012.
36. Kampen KR, Ter Elst A and de Bont ES: Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci 70: 1307-1317, 2013.